High-dose therapy and bone marrow transplantation in cutaneous T-cell lymphoma

Yu Oyama*, Joan Guitart, Timothy M. Kuzel, Richard K. Burt, Steven T. Rosen

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

27 Scopus citations


Although most patients who have cutaneous T-cell lymphoma have an indolent clinical course, patients who have cutaneous tumors, lymph node or visceral involvement, or peripheral blood involvement generally have rapidly progressive disease with shorter survival. In those patients with poor prognostic features, conventional combination chemotherapy is usually ineffective. High-dose chemotherapy with autologous hematopoietic stem cell transplant (HSCT) results in high remission rates, but the recurrence is inevitable and rapid. Allogeneic HSCT, in contrast, provides durable long-term remissions and is currently the only potentially curative therapy.

Original languageEnglish (US)
Pages (from-to)1475-1483
Number of pages9
JournalHematology/Oncology Clinics of North America
Issue number6
StatePublished - Dec 2003

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'High-dose therapy and bone marrow transplantation in cutaneous T-cell lymphoma'. Together they form a unique fingerprint.

Cite this